c-Cbl inhibition improves cardiac function and survival in response to myocardial ischemia

Khadija Rafiq1, Mikhail A Kolpakov1, Rachid Seqqat1

  • 1From the Cardiovascular Research Center and Department of Physiology, Temple University School of Medicine, Philadelphia, PA (K.R., M.A.K., R.S., J.G., X.G., Z.Q., D.Y., S.R.H., A. Sabri); Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha (B.M., N.Z., W.A., H.B.); and Department of Surgery, University of Connecticut Health Center, Farmington (A. Sanjay).

Circulation
|March 4, 2014
PubMed
Abstract

Insights

Casitas b-lineage lymphoma (c-Cbl) protein promotes heart cell death and hinders recovery after heart attacks. Inhibiting c-Cbl improves cardiac function and survival following myocardial ischemia.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Oncogene Signaling

Background:

  • Casitas b-lineage lymphoma (c-Cbl) is an E3 ubiquitin ligase involved in protein downregulation.
  • Its role in cardiac function and response to ischemia is not well understood.

Purpose of the Study:

  • To investigate the function of c-Cbl in myocyte apoptosis and cardiac function after myocardial ischemia.

Main Methods:

  • Examined c-Cbl expression in human heart disease and mouse models.
  • Utilized c-Cbl-deficient mice to assess cardiac function post-ischemia/reperfusion.
  • Measured myocyte apoptosis, protein ubiquitination, and neoangiogenesis.

Main Results:

  • Increased c-Cbl expression observed in human cardiomyopathies and under stress.
  • c-Cbl deficiency improved cardiac recovery, reduced apoptosis, and enhanced survival post-ischemia.
  • Reduced ubiquitination of survival targets and increased angiogenesis were noted in c-Cbl knockout mice.

Conclusions:

  • c-Cbl activation contributes to myocyte apoptosis, impaired angiogenesis, and adverse cardiac remodeling.
  • Targeting c-Cbl may offer a therapeutic strategy for improving cardiac function after myocardial infarction.

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K